Jake Holdreith and Ronald Schutz Named 2018 “Life Sciences Stars” by LMG Life Sciences

September 27, 2018

Robins Kaplan LLP is pleased to announce that Jake Holdreith and Ronald Schutz have been named “Life Science Stars” by LMG Life Sciences. Additionally, the firm has been recommended as a top Hatch-Waxman patent litigation firm for generic pharmaceutical companies.

Holdreith leads the firm’s Health and Life Sciences Industry Group. “Jake is not just a lawyer, he is an advisor,” noted one client in LMG’s analysis of the award. “He has a knack for understanding not only the legal ramifications of litigation strategy, but also how they interplay with business strategy.”

Schutz is the managing partner of the New York office and a leading IP trial lawyer. His advocacy skills have been recognized by numerous organizations, including Chambers, Benchmark Litigation, Managing Intellectual Property, and The National Law Journal, among others.

This is the fifth year that Holdreith and Schutz have been recognized as “Life Science Stars.” Recipients were chosen based on nearly 1,000 interviews and surveys, including firm-wide surveys, interviews with individual attorneys and clients, and a review of public information.


Jake M. Holdreith

Partner

Member of Executive Board

Ronald J. Schutz

Partner

Chair of Executive Board

Related Publications

Fourth Quarter
Generically Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Bernard Pound
Fourth Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
December 27, 2022
Takeda Pharm. Co. Ltd. v. Norwich Pharms., Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 22, 2022
Genentech, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2022
Vanda Pharms., Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top